Amado Zurita
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amado Zurita as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:52 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05873192 · Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerM.D. Anderson Cancer Center · recruiting · Prostate Cancer · principal investigator
- Ph2NCT02420587 · AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)M.D. Anderson Cancer Center · withdrawn · Prostate Cancer · principal investigator
- Ph2NCT01392183 · Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)M.D. Anderson Cancer Center · completed · Kidney Cancer · principal investigator
- Ph1NCT01262664 · A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and ObesityM.D. Anderson Cancer Center · terminated · Prostate Cancer · principal investigator
- Ph2NCT01217931 · Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START TrialM.D. Anderson Cancer Center · active not recruiting · Kidney Cancer · principal investigator
- Ph2NCT01185366 · Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell CarcinomaM.D. Anderson Cancer Center · terminated · Kidney Cancer · principal investigator
- Ph2NCT00329043 · Sunitinib Malate With Hormonal Ablation for Patients Who Will Have ProstatectomyM.D. Anderson Cancer Center · active not recruiting · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Revisiting Antiangiogenic Therapy to Target Hormone-Sensitive Prostate Cancer MetabolismR01CA275138 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 · $566,917 awarded in 2023Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:52 UTC. The ranking covers the 200 most relevant of 28 PubMed records, and a shared surname and initials can bring in a namesake. All 28 on PubMed
- 195 citationsRCR 16.1
- Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.Lancet Oncol · 2019171 citationsRCR 5.6
- A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.Ann Oncol · 2012104 citationsRCR 2.7
- Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.Clin Cancer Res · 202070 citationsRCR 2.8
- 62 citationsRCR 2.5
- Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.Nat Commun · 202157 citationsRCR 2.6
- Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.Nat Commun · 202352 citationsRCR 4.0
- 38 citationsRCR 1.3
- A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.Ann Oncol · 201738 citationsRCR 0.9
- 36 citationsRCR 1.1